Letermovir prophylaxis for cytomegalovirus is associated with risk of post-transplant lymphoproliferative disorders after haploidentical stem cell transplantation.
No abstract available
References:
Green ML, Leisenring W, Xie H, et al. . Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol. 2016;3(3):e119-e127.
Hill JA, Mayer BT, Xie H, et al. . The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality. Blood. 2017;129(16):2316-2325.
Pei XY, Zhao XY, Liu XF, et al. . Adoptive therapy with cytomegalovirus-specific T cells for cytomegalovirus infection after haploidentical stem cell transplantation and factors affecting efficacy. Am J Hematol. 2022;97(6):762-769.
Zhou JR, Shi DY, Wei R, et al. . Co-reactivation of cytomegalovirus and Epstein-Barr virus was associated with poor prognosis after allogeneic stem cell transplantation. Front Immunol. 2021;11:620891.
Anderson-Smits C, Baker ER, Hirji I. Coinfection rates and clinical outcome data for cytomegalovirus and Epstein-Barr virus in post-transplant patients: a systematic review of the literature. Transpl Infect Dis. 2020;22(6):e13396.